ArticleJournal of nephrology2025
Regional citrate anticoagulation for continuous renal replacement therapy: a prospective study in a resource-limited intensive care unit from Vietnam.
Article in Journal of nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real-World Safety and Circuit Outcomes of Protocolized Divided-Dose Enoxaparin During Continuous Renal Replacement Therapy Without Routine Anti-Xa Monitoring: A Single-Center Competing-Risk Cohort Study.Journal of clinical medicine · 2026Article
- Regional Citrate Anticoagulation in CRRT: Successes, Pitfalls, and Sustainability from a Long-Term Single-Center Experience.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRegional citrate anticoagulation has advantages over systemic heparin in prolonging filter life and decreasing bleeding risk during continuous renal replacement therapy (CRRT). However, implementing regional citrate anticoagulation in resource-limited intensive care units (ICU) remains challenging due to potential adverse events and the absence of standardized protocols. This study aims to evaluate the efficacy and safety of regional citrate anticoagulation in CRRT for critically ill patients in low-resource settings.
methodsThis single-center, prospective cohort study enrolled critically ill patients with acute kidney injury (AKI) requiring CRRT at a resource-limited ICU in Vietnam. Patients received either regional citrate anticoagulation or heparin anticoagulation. Primary outcomes included filter lifespan and adverse events; secondary outcomes were renal recovery and in-hospital mortality rate.
resultsOne hundred twenty-one patients were enrolled, 42 in the citrate group and 79 in the heparin group. The citrate group had a significantly longer filter lifespan (median 56 h versus 31 h; p < 0.001) and a lower rate of premature (< 24 h) filter clotting (4.8% versus 27.2%, p < 0.001). The hemorrhage rate was 6.4% in the citrate group versus 12.9% in the heparin group (p = 0.162). However, hypomagnesemia occurred more frequently in the citrate group (58.7% versus 23.1%, p < 0.001). No significant differences in renal recovery or hospital mortality were observed between groups.
conclusionRegional citrate anticoagulation effectively maintained filter patency and proved to be safe for CRRT in a resource-limited ICU. Further studies are needed to establish standardized protocols for regional citrate anticoagulation in this setting to minimize citrate-related adverse events.
Indexed as
Identifiers
40091003What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.